All In Biotech

Drug Trial Radar · NCT02949011

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications

Last checked: Nov 20, 2026Latest source record: Nov 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,184 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,184

Actual

Start

Jan 11, 2017

Primary completion

Apr 12, 2018

Study completion Apr 20, 2018

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Oct 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.

Conditions

  • Influenza

Interventions

  • Baloxavir MarboxilDrug

    Tablets taken orally

  • Placebo to Baloxavir MarboxilDrug

    Matching tablets taken orally

  • OseltamivirDrug

    Capsules taken orally

  • Placebo to OseltamivirDrug

    Matching placebo capsules taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Improvement of Influenza SymptomsTime frame: From Day 1 pretreatment up to Day 14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.